Clinical Positron Emission Tomography/Computed Tomography: Quarter-Century Transformation of Prostate Cancer Molecular Imaging
- Author(s)
- Chen, DC; Huang, S; Buteau, JP; Kashyap, R; Hofman, MS;
- Details
- Publication Year 2024-04,Volume 19,Issue #2,Page 261-279
- Journal Title
- PET Clinics
- Publication Type
- Review
- Abstract
- Although positron emission tomography/computed tomography (PET/CT) underwent rapid growth during the last quarter-century, becoming a new standard-of-care for imaging most cancer types, CT and bone scan remained the gold standard for patients with prostate cancer. This occurred as 2-fluorine-18-fluoro-2-deoxy-d-glucose was perceived to have a limited role owing to low sensitivity in many patients. A resurgence of interest occurred with the use of fluorine-18-sodium-fluoride PET/CT as a replacement for bone scintigraphy, and then choline, fluciclovine, and dihydrotestosterone (DHT) PET/CT as prostate "specific" radiotracers. The last decade, however, has seen a true revolution with the meteoric rise of prostate-specific membrane antigen PET/CT.
- Publisher
- Elsevier
- Keywords
- Male; Humans; *Positron Emission Tomography Computed Tomography/methods; *Prostatic Neoplasms/diagnostic imaging; Fluorine Radioisotopes; Molecular Imaging; Gallium Radioisotopes; Pet; Pet/ct; Psma; Prostate-specific membrane antigen; Radiopharmaceuticals; Radiotracers
- Department(s)
- Cancer Imaging
- Publisher's Version
- https://doi.org/10.1016/j.cpet.2023.12.011
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-04-02 01:32:28
Last Modified: 2024-04-02 01:32:43